AKT1 and hepatocellular carcinoma: Han et al. found using sorafenib-resistant HCC cells generated from sorafenib-sensitive human HCC cells that continuous exposure to sorafenib increased hepatocyte growth factor production and c-Met phosphorylation, leading to the activation of AKT and ERK pathways (Han et al., 2017).